Geode Capital Management LLC Trims Position in 23andMe Holding Co. (NASDAQ:ME)

Geode Capital Management LLC lowered its position in shares of 23andMe Holding Co. (NASDAQ:ME) by 95.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 207,995 shares of the company’s stock after selling 4,038,098 shares during the period. Geode Capital Management LLC owned about 0.80% of 23andMe worth $676,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Virtu Financial LLC purchased a new position in 23andMe during the 4th quarter worth $49,000. MassMutual Private Wealth & Trust FSB acquired a new stake in shares of 23andMe during the 4th quarter worth approximately $40,000. Leavell Investment Management Inc. acquired a new position in shares of 23andMe in the fourth quarter worth about $32,000. Finally, FNY Investment Advisers LLC acquired a new stake in 23andMe in the fourth quarter valued at approximately $26,000. Institutional investors own 36.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 23andMe in a research report on Saturday, March 22nd.

23andMe Trading Down 35.3 %

23andMe stock opened at $0.50 on Friday. The stock has a market cap of $13.36 million, a P/E ratio of -0.03 and a beta of 1.19. 23andMe Holding Co. has a 12-month low of $0.53 and a 12-month high of $12.76. The company has a 50-day moving average price of $1.01 and a 200 day moving average price of $2.71.

23andMe (NASDAQ:ME) last issued its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.